講演情報
[SY-49]Cultural Psychopharmacology: Integrating Genetics, Ethnicity, and Global Perspectives
Itsuo Asai1, Mario Braakman2, Ahmad Hatim bin Hatim3 (1. Heart Clinic Medical Corporation (Japan), 2. Tilburg University (Netherlands), 3. University of Malaya (Malaysia))
キーワード：
Pharmacogenetics、Psychotropic Drugs、Ethnic Groups、Tardive Dyskinesia、Cross-Cultural Comparison
Cultural psychopharmacology, an emerging field at the intersection of psychiatry, pharmacogenomics, and anthropology, aims to understand how genetic and cultural factors together influence patients’ responses to psychotropic medications. This symposium offers an integrated perspective covering historical roots, comparative studies, and clinical results.
Prof. Mario Braakman (Tilburg University, Netherlands), with decades of experience in psychiatry and psychopharmacology, will start with a historical and conceptual overview. He will highlight key milestones in recognizing cultural diversity in treatment responses and place cultural psychopharmacology within the broader evolution of biological psychiatry.
Dr. Itsuo Asai (Heart Clinic Medical Corporation, Japan) will share comparative findings on CYP2D6 polymorphisms, culturally influenced prescribing practices, and BMI-related dose adjustments in antipsychotics across the U.S., China, and Japan. His analysis emphasizes how genetic metabolism, cultural prescribing norms, and patient body composition interact to shape real-world treatment practices and outcomes.
Prof. Ahmad Hatim Sulaiman from Universiti Malaya, Malaysia, will present his original research on tardive dyskinesia (TD) among schizophrenia patients in Malaysia. His findings show that ethnicity and treatment duration are significant predictors of TD risk, highlighting the need for ethnically sensitive pharmacovigilance in psychopharmacology.
Together, these presentations demonstrate how biology “loads the gun,” while culture “pulls the trigger.” By integrating genetics, BMI, and cultural context, cultural psychopharmacology seeks to advance safer, more effective, and culturally sensitive psychiatric care worldwide.
Prof. Mario Braakman (Tilburg University, Netherlands), with decades of experience in psychiatry and psychopharmacology, will start with a historical and conceptual overview. He will highlight key milestones in recognizing cultural diversity in treatment responses and place cultural psychopharmacology within the broader evolution of biological psychiatry.
Dr. Itsuo Asai (Heart Clinic Medical Corporation, Japan) will share comparative findings on CYP2D6 polymorphisms, culturally influenced prescribing practices, and BMI-related dose adjustments in antipsychotics across the U.S., China, and Japan. His analysis emphasizes how genetic metabolism, cultural prescribing norms, and patient body composition interact to shape real-world treatment practices and outcomes.
Prof. Ahmad Hatim Sulaiman from Universiti Malaya, Malaysia, will present his original research on tardive dyskinesia (TD) among schizophrenia patients in Malaysia. His findings show that ethnicity and treatment duration are significant predictors of TD risk, highlighting the need for ethnically sensitive pharmacovigilance in psychopharmacology.
Together, these presentations demonstrate how biology “loads the gun,” while culture “pulls the trigger.” By integrating genetics, BMI, and cultural context, cultural psychopharmacology seeks to advance safer, more effective, and culturally sensitive psychiatric care worldwide.